Arcxis Biotechnologies And Roche Molecular Systems Initiate Research Collaboration To Apply New Technology For Diagnostic Sample Preparation

Arcxis Biotechnologies recently announced the initiation of collaboration with a business area of Hoffmann-La Roche's Diagnostic Division, Roche Molecular Systems of Pleasanton, CA. The effort will apply Arcxis' proprietary technology for isolation and concentration of total RNA and genomic DNA to PCR & RT-PCR based diagnostic tests. The company believes its rapid and sensitive methods for preparing blood and tissue will translate into significant performance benefits.

"We are very pleased to enter into this collaboration with Roche," said Christine A. Meda, President and CEO. "Partnering with a global diagnostic leader offers a unique opportunity for Arcxis to apply its technologies to the detection of infectious diseases and cancer."

"Many companies, large and small, have struggled to purify nucleic acids for molecular diagnostic tests. We believe that the application of our technology will extend the dynamic range of assays," says Dr. Jay West, CTO of Arcxis. "The technology ultimately will enhance the sensitivity of molecular diagnostic tests which could translate into better decision making for clinicians."

Arcxis Biotechnologies is a developer of systems for disease pathogen detection and clinical diagnostics headquartered in Pleasanton, California. For additional information please visit www.arcxis.com.

SOURCE: Arcxis Biotechnologies